Resmed CEO Mick Farrell (NYSE: RMD) reported “broad-based momentum” and strong 2025 third-quarter fiscal year results during the company’s April 23 earnings call. Farrell credited Resmed’s “excellent top line and bottom line results” to the company’s “disciplined execution to capture growing demand for our products. Our continued success is driven by our market-leading value proposition…
